Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets.
gene expression
molecular profiling
olfactory neuroblastoma
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 May 2021
21 May 2021
Historique:
received:
01
04
2021
revised:
18
05
2021
accepted:
20
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Olfactory neuroblastoma (ONB) is a rare sinonasal neoplasm with a peculiar behavior, for which limited prognostic factors are available. Herein, we investigate the transcriptional pathways altered in ONB and correlate them with pathological features and clinical outcomes. We analyze 32 ONB patients treated with curative intent at two independent institutions from 2001 to 2019 for whom there is available pathologic and clinical data. We perform gene expression profiling on primary ONB samples and carry out functional enrichment analysis to investigate the key pathways associated with disease-free survival (DFS). The median age is 53.5 years; all patients undergo surgery and a pure endoscopic approach is adopted in the majority of cases (81.2%). Most patients have advanced disease (stages III-IV, 81.2%) and 84.4% undergo adjuvant (chemo)radiotherapy. The median follow-up is 35 months; 11 (26.8%) patients relapse. Clinical characteristics (gender, stage and Hyams' grade) are not associated with the outcomes. In contrast, TGF-beta binding, EMT, IFN-alpha response, angiogenesis, IL2-STAT5 and IL6-JAK-STAT3 signaling pathways are enriched in patients experiencing recurrence, and significantly associated with shorter DFS. Clustering of transcriptional profiles according to pathological features indicates two distinct molecular groups, defined by either cytokeratin-positive or -negative immunostaining. Definition of the characterizing ONB transcriptomic pathways may pave the way towards tailored treatment approaches.
Identifiants
pubmed: 34064009
pii: cancers13112527
doi: 10.3390/cancers13112527
pmc: PMC8196700
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Res. 2019 Mar 15;79(6):1226-1238
pubmed: 30674534
Oncotarget. 2016 Aug 9;7(32):52584-52596
pubmed: 27256979
Sci Rep. 2015 Nov 02;5:15993
pubmed: 26522589
PLoS One. 2009;4(3):e4710
pubmed: 19270750
Breast Cancer Res. 2019 May 6;21(1):59
pubmed: 31060575
Cell Stem Cell. 2017 Jun 1;20(6):817-830.e8
pubmed: 28506465
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Cell Rep. 2018 Oct 16;25(3):811-821.e5
pubmed: 30332658
Int Forum Allergy Rhinol. 2019 Sep;9(9):1054-1062
pubmed: 31251848
Oncol Lett. 2020 May;19(5):3506-3512
pubmed: 32269624
Oncogene. 2012 Jun 28;31(26):3190-201
pubmed: 22037216
Cell Cycle. 2009 Feb 15;8(4):532-5
pubmed: 19182518
Eur J Cancer. 2013 Apr;49(6):1324-34
pubmed: 23312882
Sci Rep. 2020 Feb 27;10(1):3652
pubmed: 32107458
Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1667-71
pubmed: 20706843
Biometrics. 2008 Dec;64(4):1263-9
pubmed: 18325074
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Onco Targets Ther. 2019 Feb 18;12:1319-1331
pubmed: 30863098
Neurosurg Clin N Am. 2013 Jan;24(1):51-65
pubmed: 23174357
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Acta Neurochir (Wien). 2005 Jun;147(6):595-601; discussion 601-2
pubmed: 15806328
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Pharmacol Ther. 2021 Jan;217:107666
pubmed: 32835827
J Surg Oncol. 2019 Jan;119(1):130-142
pubmed: 30466166
Laryngoscope. 2016 Jul;126(7):1556-61
pubmed: 26865537
Mol Cell. 2001 Jul;8(1):105-13
pubmed: 11511364
Theranostics. 2020 Feb 10;10(7):3083-3098
pubmed: 32194856
Int J Clin Oncol. 2020 May;25(5):810-817
pubmed: 31919690
Mol Cancer Res. 2017 Nov;15(11):1551-1557
pubmed: 28775129